Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by REZA JOHN MEHRAN and JOHN VICTOR HEYMACH.
REZA JOHN MEHRAN
Connection Strength
1.816
JOHN VICTOR HEYMACH
  1. Tumor endothelial markers define novel subsets of cancer-specific circulating endothelial cells associated with antitumor efficacy. Cancer Res. 2014 May 15; 74(10):2731-41.
    View in: PubMed
    Score: 0.476
  2. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet. 2023 09 09; 402(10405):871-881.
    View in: PubMed
    Score: 0.227
  3. A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 07 15; 26(14):3525-3536.
    View in: PubMed
    Score: 0.181
  4. Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer. J Immunother Cancer. 2024 Oct 23; 12(10).
    View in: PubMed
    Score: 0.062
  5. Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 2024 Apr; 167(4):1444-1453.e4.
    View in: PubMed
    Score: 0.058
  6. Perioperative and oncologic outcomes of pulmonary resection for synchronous oligometastatic non-small cell lung cancer: Evidence for surgery in advanced disease. J Thorac Cardiovasc Surg. 2024 Jun; 167(6):1929-1935.e2.
    View in: PubMed
    Score: 0.057
  7. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat Med. 2023 03; 29(3):593-604.
    View in: PubMed
    Score: 0.056
  8. Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 2022 11; 164(5):1327-1337.
    View in: PubMed
    Score: 0.051
  9. Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection. Lung Cancer. 2022 02; 164:69-75.
    View in: PubMed
    Score: 0.051
  10. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. Lancet Oncol. 2021 10; 22(10):1448-1457.
    View in: PubMed
    Score: 0.050
  11. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021 03; 27(3):504-514.
    View in: PubMed
    Score: 0.048
  12. Pathological nodal disease defines survival outcomes in patients with lung cancer with tumour major pathological response following neoadjuvant chemotherapy. Eur J Cardiothorac Surg. 2021 01 04; 59(1):100-108.
    View in: PubMed
    Score: 0.048
  13. Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment. Clin Cancer Res. 2020 10 15; 26(20):5477-5486.
    View in: PubMed
    Score: 0.046
  14. Peripheral cytokines are not influenced by the type of surgical approach for non-small cell lung cancer by four weeks postoperatively. Lung Cancer. 2020 08; 146:303-309.
    View in: PubMed
    Score: 0.046
  15. Driver Mutations in Normal Airway Epithelium Elucidate Spatiotemporal Resolution of Lung Cancer. Am J Respir Crit Care Med. 2019 09 15; 200(6):742-750.
    View in: PubMed
    Score: 0.044
  16. Tumor characteristics associated with engraftment of patient-derived non-small cell lung cancer xenografts in immunocompromised mice. Cancer. 2019 11 01; 125(21):3738-3748.
    View in: PubMed
    Score: 0.043
  17. Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma. J Thorac Oncol. 2018 02; 13(2):246-257.
    View in: PubMed
    Score: 0.039
  18. Variants with a low allele frequency detected in genomic DNA affect the accuracy of mutation detection in cell-free DNA by next-generation sequencing. Cancer. 2018 03 01; 124(5):1061-1069.
    View in: PubMed
    Score: 0.038
  19. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial. Cancer. 2017 Aug 15; 123(16):3031-3039.
    View in: PubMed
    Score: 0.037
  20. Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells. Oncotarget. 2016 Jan 19; 7(3):3548-58.
    View in: PubMed
    Score: 0.034
  21. Predictive biomarkers in precision medicine and drug development against lung cancer. Chin J Cancer. 2015 Jul 02; 34(7):295-309.
    View in: PubMed
    Score: 0.033
  22. Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer. Cancer Lett. 2015 Feb 01; 357(1):179-185.
    View in: PubMed
    Score: 0.031
  23. Propensity score-matched analysis of comprehensive local therapy for oligometastatic non-small cell lung cancer that did not progress after front-line chemotherapy. Int J Radiat Oncol Biol Phys. 2014 Nov 15; 90(4):850-7.
    View in: PubMed
    Score: 0.031
  24. Endothelial progenitor cell mobilization by preoperative exercise: a bone marrow response associated with postoperative outcome. Br J Anaesth. 2014 Oct; 113(4):652-60.
    View in: PubMed
    Score: 0.030
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.